"Pfizer has a particular onus to help intervene globally as one of the largest and most profitable pharmaceutical companies in the world. With its immense capital power, Pfizer should shift some of their spending from national ads promoting their vaccine product in a country that has large booster vaccine availability to sharing the technology that can help countries self-produce and vaccinate their citizens much faster.

Even if new production facilities had delays from receiving the mRNA technology protocol to production, the months spent toward self-producing could be expediting vaccine receipt for countries otherwise waiting until the end of 2022 for donated vaccines.

In a pandemic that is approaching six million global deaths, time is the most valuable resource in fulfilling vaccine equity. Countries cannot wait to save lives while wealthy pharmaceutical companies gatekeep vital technology."

Amber Gipson-Fine is a project manager.

She shares her story and discusses her KevinMD article, "People over profit: Pfizer and Moderna must share vaccine technology."

Did you enjoy today’s episode?

Rate and review the show so more audiences can find The Podcast by KevinMD.

Subscribe on your favorite podcast app to get notified when a new episode comes out.

Reflect and earn 1.0 AMA PRA Category 1 CME for this episode.

Also available in Category 1 CME bundles.

Powered by CMEfy - a seamless way for busy clinician learners to discover Internet Point-of-Care Learning opportunities that reward AMA PRA Category 1 Credit(s)™. Learn more at about.cmefy.com/cme-info